Journal article
MRI demonstration of gadolinium deposition in bone after monthly triple-dose gadopentetate dimeglumine and correlation with frequency of hypophosphatemia
Clinical imaging, Vol.70, pp.136-141
02/2021
DOI: 10.1016/j.clinimag.2020.07.022
PMID: 33161342
Abstract
We retrospectively analyzed data of the BECOME trial to investigate whether serial administration of triple-dose (3-dose) gadopentetate dimeglumine would result in the development of T1 signal-to-noise (S/N) changes in the cranial diploic space and whether S/N changes correlated with on-study hypophosphatemia.
Signal intensity analysis was performed on the first year's data of the BECOME trial using 3-dose Gd (14 months, maximum number of doses, 39, mean: 36). Routine blood and urine tests were obtained each month for safety monitoring. Linear mixed regression modeling with random intercept was used to analyze monthly signal-to-noise ratio (S/N = Bone/Air) using an ROI of the diploic space created from T2W images and overlaid on T1FS (T1 fat-saturated) images. Incidence of phosphate abnormalities was analyzed using the general estimation equation; correlation of phosphate and S/N change was achieved with type 3 test of fixed effects.
Cranial diploic space T1FS S/N increased over 14 months: S/N = 0.039 mean monthly increase (S.E. 0.008; p < 0.0001). Subjects with consistently normal phosphate levels (n = 32) experienced more of a S/N increase than patients with at least one episode of hypophosphatemia (n = 35) (0.057 vs. 0.023, respectively, p = 0.037). Those with moderate hypophosphatemia demonstrated no significant S/N increase.
Monthly administration of 3-dose gadopentetate dimeglumine is associated with development of increased S/N on T1FS imaging in the cranial diploic space, suggesting Gd retention in bone. Our data suggests MRI could be used as a noninvasive method of tracking Gd retention in bone, which was more pronounced in patients with normal phosphate levels.
•We demonstrate previously undescribed in vivo MRI evidence of gadolinium deposition in bone in the form of increased signal-to-noise (S/N) in patients receiving serial doses of gadopentetate dimeglumine using a routine T1 sequence.•There was a relationship between gadolinium-related hypophosphatemia and rate of development of T1 hyperintensity.•Mean monthly S/N increase was significantly higher in patients who never experienced hypophosphatemia than in patients who experienced mild or moderate hypophosphatemia.
Details
- Title: Subtitle
- MRI demonstration of gadolinium deposition in bone after monthly triple-dose gadopentetate dimeglumine and correlation with frequency of hypophosphatemia
- Creators
- Devin Bageac - University of ConnecticutJohn J. DeBevits - University of ConnecticutReshma Munbodh - Brown UniversityJoshua Kaplan - Orange (Belgium)Rong Wu - University of ConnecticutPaul A. DiCamillo - University of IowaChaoran Hu - University of ConnecticutYanlin Wang - University of ConnecticutDavid Karimeddini - University of ConnecticutRobert T. Naismith - Washington University in St. LouisSuhayl Dhib-Jalbut - OrangeLeo Wolansky - University of Connecticut
- Resource Type
- Journal article
- Publication Details
- Clinical imaging, Vol.70, pp.136-141
- DOI
- 10.1016/j.clinimag.2020.07.022
- PMID
- 33161342
- NLM abbreviation
- Clin Imaging
- ISSN
- 0899-7071
- eISSN
- 1873-4499
- Publisher
- Elsevier Inc
- Grant note
- name: Guerbet; DOI: 10.13039/100004326, name: Bayer
- Language
- English
- Date published
- 02/2021
- Academic Unit
- Radiology
- Record Identifier
- 9984318804102771
Metrics
4 Record Views